Ebola vaccine from Merck takes step toward US approval

BioPharma Dive | September 17, 2019

Ebola vaccine from Merck takes step toward US approval
While Merck's Ebola vaccine isn't yet approved in the U.S. or Europe, the drugmaker has been providing extensive supplies of investigational doses at the request of the WHO. According to the company, Merck has shipped more than 245,000 1 milliliter doses of V920 to the international health agency, with another 190,000 available.  V920 is part of the international community's response to the outbreak of Ebola in the northwest corner of the DRC. The number of reported cases per week has come down from a peak several months ago, but remains high. "While the intensity of the outbreak shows signs of easing in some areas and total case numbers are decreasing, it is too soon to tell if this trend will continue," the WHO noted in its Sept. 10 situation report. As the outbreak persists, Merck has begun preparation to increase supply of investigational V920 in consultation with the WHO, the U.S. Department of Health and Human Services and Gavi, the Vaccine Alliance. Merck aims to produce 650,000 doses in phases over the next six to 18 months.

Spotlight

Know more about the global scenario of spurious drugs and why we need a traceability system.

Related News

ANDA approves Glenmark Pharmaceuticals for Sirolimus Tablets, 0.5 mg, 1 mg and 2 mg

Glenmark Pharmaceuticals Inc | October 19, 2020

Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Sirolimus Tablets, 0.5 mg, 1 mg and 2 mg, the generic version of Rapamune®1 Tablets, 0.5 mg, 1 mg and 2 mg, of PF Prism CV. According to IQVIATM sales data for the 12 month period ending August 2020, the Rapamune® Tablets, 0.5 mg, 1 mg and 2 mg market2 achieved annual sales of approximately $119.7 million*. Glenmark's current portfolio consists of 165 products authorized for distribution in the U.S. marketplace and 45 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Read More

POLICY AND REGULATION

EpiEndo Pharmaceuticals Secures Funding to Advance Clinical Development of its Non-Antibiotic Macrolide for the treatment of COPD

EpiEndo Pharmaceuticals | August 19, 2021

EpiEndo Pharmaceuticals , a privately held biopharmaceutical company focused on a novel barrier enhancing approach to the treatment of chronic inflammatory airway diseases such as chronic obstructive pulmonary disease (COPD), announces the closing of a €20m Series A financing round led by Flerie Invest and Iðunn Venture Fund, with existing investors ABC Ventures participating, along with the European Innovation Council (EIC) Fund joining the round. The financing secures funds to advance clinical development of EpiEndo’s lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication. EpiEndo’s development rationale is based on a newly acknowledged therapeutic paradigm, that loss of integrity of epithelial barriers plays a critical role in propagating chronic inflammatory diseases in lungs and contributes to vulnerability to infections associated with acute exacerbations of airway diseases. “I am delighted to announce the closing of this new investment round,” commented Maria Bech, CEO of EpiEndo Pharma. “We are very pleased to welcome such well-reputed investors as Flerie Invest and Iðunn Venture Fund to help us build our company and are honoured that the European Innovation Council Fund has chosen EpiEndo as its first follow-on investment. We are also grateful for the continued support of our existing investors. This financing is a major step for EpiEndo, not only funding our lead compound through clinical development in patients with COPD, but also enabling exploration of other important potential therapeutic application areas such as dermatology and gastrointestinal disorders, where compromised epithelial integrity is known to contribute to disease pathophysiology.” Macrolide antibiotics such as azithromycin have been known for decades to exhibit good disease modifying efficacy against many chronic inflammatory airway diseases in addition to their antibacterial properties, in which their long-term use reduces the frequency and severity of inflammatory flare-ups and exacerbations. Although beneficial for overall health and prognosis, their off-label use in these patient populations has led to the emergence of macrolide resistance in the host flora. EpiEndo’s lead compound EP395 is a new chemical entity in which the epithelial regenerative properties and anti-inflammatory effects seen with macrolides have been augmented, and the anti-bacterial properties removed. Using this Series, A funding, EpiEndo aims to advance the clinical development of EP395 towards approval as the first disease modifying non-antibiotic macrolide that can be prescribed safely and effectively as a long-term treatment for patients with COPD. “We have followed EpiEndo for some time and have seen impressive progress towards clinical phase of their lead compound EP 395. We are proud to take part in their continuing journey with the aim to deliver substantially improved treatment of COPD,” said Carl-Johan Spak, Senior Advisor at Flerie Invest. “EpiEndo is an attractive investment opportunity for Iðunn and a good fit for our fund’s investment strategy. We are looking forward to work with the company in the coming years to develop its lead candidate through the coming clinical phases. It is important for Iðunn to participate in the translation of new scientific discovery into clinical practice,” commented Hilmar Bragi Janusson, Managing Director of Iðunn Venture Fund. “ABC is thrilled to obtain, in this round, a group of new investors to co-lead with us and support EpiEndo´s quest to create a solution to some of the most problematic diseases,” commented Ivar Gudjonsson, Managing Director of ABC Venture and a board member of EpiEndo. “EpiEndo Pharmaceuticals’ challenge is to develop a new class of drugs and we are delighted to take part in this scale up journey,” said José Fernando Figueiredo, EIC Fund Investment Committee member, “The EIC Fund is taking part in this financial round to help this great example of a life science company to develop and deploy breakthrough treatment of chronic obstructive inflammatory pulmonary disease.” About EpiEndo Pharmaceuticals EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to inflammatory disorders that focuses on enhancement of epithelial barrier integrity as a critical pathophysiological factor underlying the etiology of a number of major diseases. Epithelial cells are a key component of the barrier that makes up human lung tissue and other organs such as the gut and skin. Compromised integrity of this barrier is implicated in the progression and non-resolution of several chronic inflammatory diseases. EpiEndo is developing a proprietary portfolio of orally available macrolide drugs with promise as first-in-class disease-modifying therapeutics, to address the huge global burden of chronic diseases of the lung and other organs where there is other significant unmet medical need. EpiEndo’s lead drug candidate, EP395, aims to be the first on-market oral, non-antibiotic, barrier strengthening and anti-inflammatory macrolide for the treatment of COPD.

Read More

RESEARCH

Nanoform and Celanese Explore Ways to Improve Drug Delivery

Nanoform, Celanese | May 26, 2021

Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, and Celanese Corporation, a global specialty materials company, announced today plans to investigate potential synergies in the field of nanoparticle-enabled drug delivery. The objective of this research is to determine the utility of combining Nanoform's nanoparticle platform technologies with Celanese's VitalDose® EVA copolymer delivery technology for drug-eluting implants. The objectives are to enable the development of next-generation drug delivery systems that can handle an increased drug load and have better-sustained release properties. Nanoform and Celanese intend to collaborate on formulation development, using each company's formulation expertise. "We are excited to announce our collaboration with Celanese. One of Nanoform's primary goals is to allow next-generation drug therapies through the use of our nanoparticles. Given the inherent difficulty in loading an adequate amount of drug into many medical devices, we see a huge opportunity in employing our nanoparticles to overcome this fundamental challenge. We are excited about the potential to use the combination of these two technologies to provide new therapies to patients "said Nanoform CEO Edward Hggström. "Celanese has a good track record of developing drug-eluting implants for women's health, ophthalmology, and central nervous system disorders by integrating our VitalDose® EVA copolymer delivery technology with proteins, peptides, and small molecules. Exploring Nanoform's nanoparticle technologies offers up new possibilities for enhancing formulation performance with existing products and enabling future products. We are excited to collaborate with Nanoform and hope that our efforts will result in innovations that will benefit patients "Laura Brand, Celanese Vice President of Medical & Pharmaceuticals, said.

Read More

Spotlight

Know more about the global scenario of spurious drugs and why we need a traceability system.